Best for
All-rounder
How to buy AgeX Therapeutics shares | $0.795
Own AgeX Therapeutics shares in just a few minutes. Share price changes are updated daily.
AgeX Therapeutics, Inc (AGE) is a leading biotechnology business based in the US. It opened the day at $0.8379 after a previous close of $0.798. During the day the price has varied from a low of $0.7753 to a high of $0.87. The latest price was $0.795 (25 minute delay). AgeX Therapeutics is listed on the NYSE MKT and employs 17 staff. All prices are listed in US Dollars.
How to buy shares in AgeX Therapeutics
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: AGE in this case.
- Research AgeX Therapeutics shares. The platform should provide the latest information available.
- Buy your AgeX Therapeutics shares. It's that simple.
Best for
Low-cost trading
Best for
US shares
Best for
Beginners
What's in this guide?
- Can I buy shares in AgeX Therapeutics?
- Has coronavirus impacted AgeX Therapeutics shares?
- AgeX Therapeutics shares summary
- Compare share dealing platforms
- Is AgeX Therapeutics stock a buy or sell?
- AgeX Therapeutics performance over time
- Can I short AgeX Therapeutics shares?
- AgeX Therapeutics's financials
- Does AgeX Therapeutics pay a dividend?
- Have AgeX Therapeutics shares ever split?
- Other common questions
How has Coronavirus impacted AgeX Therapeutics's share price?
Since the stock market crash in March caused by coronavirus, AgeX Therapeutics's share price has had significant positive movement.
Its last market close was $1.78, which is 25.84% up on its pre-crash value of $1.32 and 137.33% up on the lowest point reached during the March crash when the shares fell as low as $0.75.
If you had bought $1,000 worth of AgeX Therapeutics shares at the start of February 2020, those shares would have been worth $625.96 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,358.78.
AgeX Therapeutics share price
Use our graph to track the performance of AGE stocks over time.AgeX Therapeutics shares at a glance
Information last updated 2020-09-29.
| Open | $0.8379 |
|---|---|
| High | $0.87 |
| Low | $0.7753 |
| Close | $0.795 |
| Previous close | $0.798 |
| Change | $-0.003 |
| Change % | -0.376% |
| Volume | 282,306 |
Information last updated 2020-10-21.
| 52-week range | $0.68 - $2.59 |
|---|---|
| 50-day moving average | $1.1227 |
| 200-day moving average | $0.9893 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.318 |
Invest in AgeX Therapeutics shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
Is it a good time to buy AgeX Therapeutics stock?
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
AgeX Therapeutics price performance over time
Historical closes compared with the last close of $0.795
| 1 week (2020-10-15) | -54.57% |
|---|---|
| 1 month (2020-09-25) | -5.36% |
| 3 months (2020-07-24) | -40.23% |
| 6 months (2020-04-24) | -7.45% |
| 1 year (2019-10-25) | -49.36% |
|---|
AgeX Therapeutics financials
| Revenue TTM | $1.9 million |
|---|---|
| Gross profit TTM | $1.5 million |
| Return on assets TTM | -98.37% |
| Return on equity TTM | -453.02% |
| Profit margin | 0% |
| Book value | $0.115 |
| Market capitalisation | $62.6 million |
TTM: trailing 12 months
How to short and sell AgeX Therapeutics shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "AGE.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 1.4 million AgeX Therapeutics shares held short by investors – that's known as AgeX Therapeutics's "short interest". This figure is 0.9% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting AgeX Therapeutics shares can be evaluated.
AgeX Therapeutics's "short interest ratio" (SIR)
AgeX Therapeutics's "short interest ratio" (SIR) is the quantity of AgeX Therapeutics shares currently shorted divided by the average quantity of AgeX Therapeutics shares traded daily (recently around 173190.71518193). AgeX Therapeutics's SIR currently stands at 7.97. In other words for every 100,000 AgeX Therapeutics shares traded daily on the market, roughly 7970 shares are currently held short.
However AgeX Therapeutics's short interest can also be evaluated against the total number of AgeX Therapeutics shares, or, against the total number of tradable AgeX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AgeX Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AgeX Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.065% of the tradable shares (for every 100,000 tradable AgeX Therapeutics shares, roughly 65 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AgeX Therapeutics.
Find out more about how you can short AgeX Therapeutics stock.
AgeX Therapeutics share dividends
We're not expecting AgeX Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have AgeX Therapeutics's shares ever split?
AgeX Therapeutics's shares were split on a 15:16 basis on 6 May 2015. So if you had owned 16 shares the day before before the split, the next day you'd have owned 15 shares. This wouldn't directly have changed the overall worth of your AgeX Therapeutics shares – just the quantity. However, indirectly, the new 6.7% higher share price could have impacted the market appetite for AgeX Therapeutics shares which in turn could have impacted AgeX Therapeutics's share price.
AgeX Therapeutics overview
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
Frequently asked questions
More guides on Finder
-
How to buy Virpax Pharmaceuticals (VRPX) shares when it goes public
Everything we know about the Virpax Pharmaceuticals IPO, plus information on how to buy it.
-
How to buy Vivos Therapeutics (VVOS) shares when it goes public
Everything we know about the Vivos Therapeutics IPO, plus information on how to buy it.
-
How to buy Kiromic Biopharma (KRBP) shares when it goes public
Everything we know about the Kiromic Biopharma IPO, plus information on how to buy it.
-
How to buy Codiak BioSciences (CDAK) shares when it goes public
Everything we know about the Codiak BioSciences IPO, plus information on how to buy it.
-
How to buy Triller (AGE.US) shares when it goes public
Everything we know about the Triller IPO, plus information on how to buy it.
-
How to buy Eastern Bank (EBC) shares when it goes public
Everything we know about the Eastern Bank IPO, plus information on how to buy it.
-
How to buy Wish (AGE.US) shares when it goes public
Everything we know about the Wish IPO, plus information on how to buy it.
-
How to buy MINISO Group Holding Limited (MNSO) shares when it goes public
Everything we know about the MINISO Group Holding Limited IPO, plus information on how to buy it.
-
How to buy Playboy (PLBY) shares when it goes public
Everything we know about the Playboy IPO, plus information on how to buy it.
-
How to buy iHuman (IH) shares
Everything we know about the iHuman IPO, plus information on how to buy it.
Ask an Expert